Deuterated i soindolineI, 3-dione derivatives as PDE4 and TNF-alpha inhibitors

Details for Australian Patent Application No. 2010260249 (hide)

Owner Concert Pharmaceuticals, Inc.

Inventors Liu, Julie F.

Agent Davies Collison Cave

Pub. Number AU-A-2010260249

PCT Pub. Number WO2010/147922

Priority 61/268,953 18.06.09 US

Filing date 15 June 2010

Wipo publication date 23 December 2010

International Classifications

C07D 209/46 (2006.01) Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom

A61K 31/4035 (2006.01)

A61P 17/06 (2006.01) Drugs for dermatological disorders

C07D 209/48 (2006.01) Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 405/12 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

Event Publications

19 January 2012 PCT application entered the National Phase

  PCT publication WO2010/147922 Priority application(s): WO2010/147922

29 March 2012 Amendment Made

  The nature of the amendment is: Amend the invention title to read Deuterated isoindoline1,3-dione derivatives as PDE4 and TNF-alpha inhibitors

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010260251-High-density fiber optic modules and module housings and related equipment

2010260244-Disubstituted phthalazine hedgehog pathway antagonists